

UCSF

UC San Francisco Previously Published Works

Title

Depression, Religiosity, and Telomere Length in the Study on Stress, Spirituality, and Health (SSSH)

Permalink

<https://escholarship.org/uc/item/425951hg>

Journal

International Journal of Mental Health and Addiction, 20(3)

ISSN

1557-1874

Authors

Isehunwa, Oluwaseyi O

Warner, Erica T

Spiegelman, Donna

et al.

Publication Date

2022-06-01

DOI

10.1007/s11469-020-00455-1

Peer reviewed



Published in final edited form as:

Int J Ment Health Addict. 2022 June ; 20(3): 1465–1484. doi:10.1007/s11469-020-00455-1.

Depression, religiosity, and telomere length in the Study on Stress, Spirituality, and Health (SSSH)

Oluwaseyi O. Isehunwa¹,
Erica T. Warner^{1,2},
Donna Spiegelman³,
Ying Zhang¹,
Julie R. Palmer^{4,5},
Alka M. Kanaya⁶,
Shelley A. Cole⁷,
Shelley S. Tworoger^{8,9},
Lester Orville Shields¹⁰,
Yue Gu¹,
Blake Victor Kent¹,
Immaculata De Vivo^{11,12},
Alexandra E. Shields¹

National Consortium on Psychosocial Stress, Spirituality, and Health

¹MGH/Harvard Center on Genomics, Vulnerable Populations, and Health Disparities, Mongan Institute, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA

²Clinical Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

³Department of Biostatistics and Global Health, Yale School of Public Health, New Haven, CT, USA; Center for Methods on Implementation and Prevention Science, Yale School of Public Health, New Haven, CT, USA; Department of Statistics and Data Science, Yale University, New Haven, CT, USA

⁴Slone Epidemiology Center, Boston University, Boston, MA, USA

Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. <http://www.springer.com/gb/open-access/authors-rights/aam-terms-v1>

Corresponding author: Oluwaseyi O. Isehunwa, Massachusetts General Hospital, 55 Fruit Street, MA 02114, Phone: 617-643-8194; oisehunwa@mgh.harvard.edu.

Disclosure statement

The authors declare that they have no competing interests.

Declarations of interest: none

Ethics Approval: All studies obtained institutional approval for cohort maintenance, as well as participation in the SSSH. SSSH protocols were approved by the Partners Human Research Committee, the Institutional Review Board (IRB) of Partners HealthCare (Boston, MA).

Publisher's Disclaimer: This Author Accepted Manuscript is a PDF file of a an unedited peer-reviewed manuscript that has been accepted for publication but has not been copyedited or corrected. The official version of record that is published in the journal is kept up to date and so may therefore differ from this version.

⁵Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA

⁶Division of General Internal Medicine, University of California, San Francisco (UCSF), San Francisco, CA, USA

⁷Population Health Program, Texas Biomedical Research Institute San Antonio, TX, USA

⁸Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

⁹Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

¹⁰Department of Psychology, University of the West Indies – Mona, Kingston, Jamaica

¹¹Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

¹²Program in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, MA, USA

Abstract

Prospective studies on the association between depression and telomere length have produced mixed results and have been largely limited to European ancestry populations. We examined the associations between depression and telomere length, and the modifying influence of religion and spirituality, in four cohorts, each representing a different race/ethnic population. Relative leukocyte telomere length (RTL) was measured by a quantitative polymerase chain reaction. Our result showed that depression was not associated with RTL (percent difference: 3.0 95% CI: -3.9, 10.5; $p = 0.41$; p -heterogeneity across studies = 0.67) overall or in cohort-specific analyses. However, in cohort-specific analyses, there was some evidence of effect modification by the extent of religiosity or spirituality, religious congregation membership, and group prayer. Further research is needed to investigate prospective associations between depression and telomere length, and the resources of resilience including dimensions of religion and spirituality that may impact such dynamics in diverse racial/ethnic populations.

Keywords

Telomere length; Depression; Religiosity; Spirituality

Introduction

Depression, a leading public health issue in the United States and worldwide (GBD, 2016; Park & Zarate, 2019) is a severely disabling disease that has been linked to the onset of cardiovascular disease (Ford et al., 1998; Pan, Sun, et al., 2011), type 2 diabetes (Rotella & Mannucci, 2013), cancer (Julin et al., 2015), and several other age-related conditions (Aarmland et al., 2011; Danese et al., 2009). Although the biological mechanisms underlying the association between depression and these chronic diseases are not fully understood, one plausible mechanism is the shortening of telomeres mediated by immune dysregulation or oxidative stress, eventually leading to accelerated biological aging (Wolkowitz et al., 2010).

Accelerated shortening of telomeres, the protective caps at the end of chromosomes (Blackburn, 2001), has emerged as a powerful biomarker of cellular biological aging (Mather et al., 2011; Sanders & Newman, 2013) and cumulative stress (Reichert & Stier, 2017; Wolkowitz et al., 2010). Dozens of studies have demonstrated a cross-sectional relationship between depression and shorter telomere length (Lin et al., 2016; Schutte & Malouff, 2015). Recent meta-analyses including up to 38 studies (16 cross-sectional, 17 case-control, and 5 prospective cohort studies) confirmed an association between depression and shorter telomere length (Cohen's $d = -0.205$, $p < 0.0001$) (Lin et al., 2016; Ridout et al., 2016; Schutte & Malouff, 2015), although longitudinal study designs have produced far more mixed results.

To date, ten prospective studies have examined the relationship between depression and telomere attrition, with a follow-up period ranging from 2–12 years. Of the ten studies, four found a significant association between depression and shorter telomere length over time (Shalev et al., 2014; Vance et al., 2018; Verhoeven et al., 2018; Verhoeven et al., 2016), while six reported null results (Chang, Crous-Bou, et al., 2018a, 2018b; Hoen et al., 2011; Hoen et al., 2013; Rius-Ottenheim et al., 2012; Verhoeven et al., 2019). These conflicting results could be due to methodological differences in depression assessment, study participant characteristics, use of different covariates, or duration of follow-up in the study populations. Moreover, there are several limitations to extant studies. Minority racial/ethnic communities, many of which suffer disproportionately from persistent and severe depression (Bailey et al., 2019; Gonzalez et al., 2010), have not been well represented in the prospective studies of depression and telomere length. Further, studies assessing potential mitigating influences are also lacking, such as potential sources of resilience (e.g., religiosity or spirituality (R/S)) that may attenuate telomere shortening. R/S plays an important role in many racial/ethnic communities across the U.S. and could be an important coping tool that improves resilience in adverse or stressful conditions (Koenig et al., 2012), thereby providing some protection to depressed individuals and mitigate the process of cellular aging. A previous study reported a buffering effect of religiosity against depression on poor physical health (Wink et al., 2005). Similarly, a prior study also observed a protective effect of religiosity on suicidal behaviors among depressed patients with a history of childhood abuse (Dervic et al., 2006).

To address these gaps in the literature, we assessed the relationship between depression and telomere length with consideration for a potential buffering effect of religion and spirituality. We did so among 2,908 Black, South Asian, American Indian, and White participants in the Study on Stress, Spirituality, and Health. We hypothesized that depression would be associated with shorter telomere length, controlling for relevant confounders and that this association would be modified by measures of religiosity and spirituality (R/S).

Methods

The Study on Stress, Spirituality, and Health (SSSH)

The analyses presented are from a subset of participants in the Study on Stress, Spirituality, and Health (SSSH) under the auspices of the National Consortium on Psychosocial Stress, Spirituality, and Health. This Consortium, established in 2016, is designed to examine the

underlying mechanisms through which psychosocial stress contributes to chronic disease and the extent to which these associations are moderated or mediated by religious/spiritual practices or beliefs across diverse racial/ethnic communities. The Consortium includes a sample of participants from five US-based cohorts: Black Women's Health Study (BWHS) (Rosenberg et al., 1995), Mediators of Atherosclerosis in South Asians Living in America (MASALA) (Kanaya et al., 2014), Strong Heart Study (SHS), Hispanic Community Health Study / Study of Latinos (HCHS/SOL) (Lavange et al., 2010), and Nurses' Health Study II (NHSII) (Setty et al., 2007), as well as two Brazilian prospective cohort studies (Baependi and Advento (Egan et al., 2016; Franco-de-Moraes et al., 2017) that completed the SSSH baseline Spirituality Survey and had a blood sample assayed for telomere length. Historical data on demographics, lifestyle, behavioral factors, and chronic disease endpoints for SSSH participants were provided by each cohort and merged with the SSSH baseline Spirituality Survey data to create a multi-cohort analytic file. Available biomarker and questionnaire data from each cohort were centrally collated and harmonized at the Harvard/MGH Center on Genomics, Vulnerable Populations, and Health Disparities at Massachusetts General Hospital. All studies obtained institutional approval for cohort maintenance, as well as participation in the SSSH. SSSH protocols were approved by the Partners Human Research Committee, the Institutional Review Board (IRB) of Partners HealthCare (Boston, MA).

Study Populations

This analysis includes 2,908 participants (443 men and 2,465 women) from four SSSH cohorts with data on depression and telomere length: BWHS, MASALA, NHSII, and SHS.—BWHS is a prospective cohort study of African American women across the U.S. In 1995, 59,000 African American women aged 21–69 years were enrolled through self-administered questionnaires mailed to subscribers of *Essence* magazine, members of black women's professional organizations, as well as the friends and relatives of early respondents (Rosenberg et al., 1995). Information on several components including demographics, lifestyle factors, and medical history were collected at baseline and updated biennially (Rosenberg et al., 1995). This study includes 1,000 women randomly selected from among 2,463 BWHS participants who completed the SSSH R/S survey in 2016–2017 and provided a blood sample between 2013 and 2017 (Lu et al., 2019). Blood samples were collected at Quest Diagnostics Patient Service Centers and processed by Quest Diagnostic regional laboratories; and frozen aliquoted samples were shipped and stored at a temperature of -80°C at the Boston University Core Genetics Facility (Lu et al., 2019). Leukocyte telomere assays were successfully completed for 997 women. Among 997 women, we excluded 21 participants that failed to complete core questions in the R/S survey. A total of 976 BWHS participants were included in the current analysis.

MASALA is a community-based prospective cohort of 906 South Asian men and women, aged 40–84 years that were enrolled into the study between 2010 and 2013 from two clinical field centers - University of California, San Francisco (UCSF) and Northwestern University, Chicago (Kanaya et al., 2014). To be eligible, participants were required not to have any known cardiovascular disease and not to have undergone any heart or blood vessel procedures (Kanaya et al., 2014). At their in-person baseline examination, MASALA participants completed questionnaires on sociodemographic, lifestyle and behavioral factors,

and provided a fasting blood sample. Of the 906 participants, 696 provided consent for DNA extraction. Blood samples were collected by certified phlebotomists or nurses at the two clinical field centers; aliquoted samples were processed and stored at USCF for future use (Kanaya et al., 2013). Between 2015 and 2018, participants were invited back for a follow-up examination where the SSSH R/S survey was administered. Our sample population includes 574 MASALA participants for whom historic data, R/S survey, DNA samples were all available. We excluded participants with failed telomere assay (N=3), incomplete data on the main R/S questions in the R/S survey (N=98), leaving a sample of 473 MASALA participants.

NHSII is a prospective cohort study that began in 1989 when 116,671 female registered nurses from 15 U.S. States aged 25–42 years completed and returned mailed questionnaires (Setty et al., 2007). Participants receive follow-up questionnaires biennially to update lifestyle, health, and medical history, with an average response rate greater than 90% (Setty et al., 2007). In 2016, all eligible women (those who previously provided a blood sample and completed the most recent wave of data collection) were invited to complete the R/S survey; 4,268 women returned the survey. Heparin samples were collected through mailed kits between 2010–2013 or for a subset of women in 2015; samples were returned to the lab on ice by overnight shipping where it was processed into plasma, white blood cells, and red blood cells and frozen in the vapor phase of liquid nitrogen freezers (Huang et al., 2016; Huang et al., 2019). Leukocyte telomere assays were completed for 1,131 NHSII participants. We excluded participants whose telomere assay failed to run (N=1), outlier (N=1), missing data on depression (N=10), two with missing information on the use of antidepressants (N=2), and participants with missing data on the main core questions in the R/S survey (N=133). A total of 984 NHSII participants were included in the current analysis.

SHS began as a population-based, longitudinal cohort of 4,549 American Indians from 13 communities in three geographical areas: Arizona, North and South Dakota, and Oklahoma (North et al., 2003). The Strong Heart Family Study (SHFS), from which SSSH participants are drawn, is a component of the SHS that began in 2001–2003 (Phase IV) and consists of 3,776 participants (14–93 years old) from 94 extended families ascertained from sibships in the original Strong Heart Study (North et al., 2003; Storti et al., 2009). A follow-up clinical examination for SHFS participants was conducted in 2006–2009 (Phase V). This present study includes participants in Phase IV or Phase V who were enrolled in the SSSH and completed the R/S survey and for whom DNA samples were successfully assayed for leukocyte telomere length (N=731). We excluded 111 participants with missing data on depression, 26 with missing data on anti-depressant use, and 119 participants with missing data on core questions in the R/S survey, thus including 475 SHS participants in this analysis.

Measures

Depression—Data on depressive symptoms were collected via the 20-item Center for Epidemiologic Studies Depression Scale (CES-D) (Radloff, 1977) in 2005 (BWHS), 2010–2013 (MASALA) or 2001–2003 (SHS) and via the five-item Mental Health Index (MHI-5) from the Short-Form Health Survey Questionnaire (SF-36) (Ware, 2000) in 2001 (NHSII).

The CES-D measures the severity of depressive symptoms in community settings (Radloff, 1977), with high reliability and validity in detecting the presence and the severity of depressive symptoms (Van Dam & Earleywine, 2011). Respondents were asked to report on the frequency of specific feelings or behaviors during the past week, with the following response options: rarely or none (less than 1 day), some or little (1–2 days), moderate (3–4 days), or most of the time (5–7 days). Total scores ranging from 0 to 60 and a cutoff point

16 has traditionally been used to indicate the presence of severe depressive symptoms (Wise et al., 2006). The MHI-5 has also been validated and found to have high sensitivity and specificity for detecting major depression (McHorney et al., 1994; Ware, 2000). Using the MHI-5 in NHSII, respondents rate the frequency of particular feelings over the past four weeks to questions pertaining to their mental health, including depression and anxiety, with answers ranging from all, most, a good bit, some, a little, or none of the time. Participant scores range from 5 to 30, using a standard linear transformation they were standardized to include a range from 0 to 100 with high scores indicating better mental health (McHorney et al., 1994; Ware, 2000). As in several previous studies (Chang, Crous-Bou, et al., 2018a; Pan, Okereke, et al., 2011), we used MHI-5 score ≥ 52 to indicate the presence of severe depressive symptoms.

Antidepressant use was determined via self-report and/or medication inventory. In BWHS, antidepressant medication use was ascertained in 2005 by the question, “Do you take any of the following medications or vitamins at least 3 days a week?” Patients who marked yes for “Antidepressants (Prozac, Zoloft, Elavil, etc.)” were classified as using antidepressant medications. The questionnaire also included the open-ended question, “Please list all other medications or supplements that you currently take at least 3 days a week,” which was used to identify additional users of antidepressant medications. In MASALA, the use of antidepressant medication was ascertained (2010–2013) by the question, “Are you taking any prescription medications, over-the-counter medications, vitamins, herbs or supplements?” For participants that responded “yes” to this question, the medication was verified and recorded by the interviewer. In SHS, participants were asked to bring their current medications to their clinical examination (2001–2003). The name, strength, and the total number of doses prescribed per day, week, or month was recorded by the interviewer. In NHSII, antidepressant medication use was ascertained in 2001 by the question “Mark if used regularly in the past 2 years:” “Prozac,” “Zoloft,” “Paxil,” “Celexa,” and “other antidepressants” (e.g. Elavil, Tofranil, Pamelor).

In secondary analyses, we cross-classified participants according to various combinations of severe depressive symptoms and use of antidepressants: (1) severe depressive symptoms and antidepressant use; (2) severe depressive symptoms and antidepressant use, (3) severe depressive symptoms without antidepressant use, and (4) antidepressant use only.

Religiosity and spirituality dimensions

Data on measures of religiosity and spirituality (R/S) were obtained from the baseline SSSH Spirituality Survey, which collected data across the cohorts sometime between 2016 and 2019. For this study, we considered R/S measures that captured key aspects of this multidimensional construct hypothesized to moderate the depression-telomere length

relationship. R/S measures included five validated and two *de novo* measures. The first came from the Brief Multidimensional Measure of Religion and Spirituality (Fetzer, 1999): self-described extent of religiosity or spirituality ["To what extent do you consider yourself a religious or spiritual person?" dichotomized as "very religious"=1 and "moderately," "slightly," or "not at all"=0]. The second and third measures came from the Duke Religion Index (Koenig & Büssing, 2010) : frequency of religious services attendance, [How often do you attend religious services?" dichotomized as frequently ("several times per week" or "once a week"=1) and not frequently ("2–3 times per month," "about once a month," "rarely" or "never")=0]; and frequency of private prayer, ["How often do you pray by yourself?" dichotomized as frequently ("several times a day" or "once a day"=1) and not frequently ("more than once a week," "once a week," "several times a month," "several times a year," or "never"=0)]. Two items were *de novo*, created with the input of R/S experts and the help of participant focus groups: being part of a religious congregation or community ("yes"=1); and frequency of group prayer ["How often do you pray in a group other than at a religious service?" dichotomized identically to the item on private prayer. The final two items came from the Religious Coping Scale (Pargament et al., 2000): positive religious coping consisted of seven items in response to a question stem about facing stressful situations (e.g., "I saw my situation as part of God's plan," "I tried to make sense of the situation with God," "I worked together with God to relieve my worries"); negative religious coping was measured with six items (e.g., "I wondered what I did for God to punish me," "I questioned God's love or care for me," "I wondered whether God had abandoned me"). Responses to each of the religious coping items ranged from 1= "not at all" to 4 = "a great deal." Scores were summed and dichotomized based on the median score (above median=1).

Social support

We assessed social support as another resource for resilience using the Berkman-Symes Social Networks Index (Berkman & Syme, 1979) or ENRICH Social Support Index (Berkman et al., 2000; Mitchell et al., 2003). The Berkman-Symes (BS) Social Networks Index was used in BWHS (2010), SHS (2018), and NHSII (2013). It asked, "Can you count on anyone to provide you with emotional support (talking over problems or helping you make a difficult decision?)" using a 5-point response scale ("none of the time" to "all of the time"). "Some of the time," "most of the time", and "all of the time" were categorized as having social support (=1), while "a little of the time" and "none of the time" were categorized as having no social support (=0). In addition to the above, those answering "Yes, monthly" or "Yes, weekly" or "Yes, daily" to the question ("Is there anyone special person you know that you feel very close to; someone you feel you can share confidences and feelings with?") asked of participants in NHSII (2013) was also classified as having social support. In MASALA, three questions from the ENRICH Social Support Index assessed whether someone provides emotional support, shows love or affection, and can be trusted. Each question used a 5-point scale ("none of the time" =1 to "all of the time" =5). Responses were summed and those with scores ≥ 12 were categorized as having social support (Lagisetty et al., 2016).

Covariates

We considered covariates known to be associated with depression or telomere length (Bruin et al., 2018; Valdes et al., 2005), including demographics (age, gender, employment status, educational attainment, and employment status); lifestyle factors (smoking status, Alternative Healthy Eating Index with alcohol [AHEI], and physical activity); and other health-related factors (presence of hypertension, use of antidepressants). We used the most recent available data prior to or at the time of exposure: 2001, 2003, & 2005 (BWHS), 2010–2013 (MASALA), 2001–2003 (SHS), and 2001 (NHSII). The 2009 and 2011 NHSII questionnaires provided data on physical activity and AHEI in NHSII participants respectively. Body mass index (BMI) was computed using the person's weight in kilograms divided by the square of a person's height in meters (kg/m^2). Physical activity was measured as in MET-hour/week in BWHS, MASALA, and NHSII, but as average pedometer steps/week in SHS.

Telomere length

All telomere assays were performed in the DeVivo Laboratory at Brigham and Women's Hospital (Boston, MA). Genomic DNA was isolated from peripheral blood leukocytes using the QIAmp 96-spin blood protocol (Qiagen, Chatsworth, CA). Relative leukocyte telomere length (RTL) was measured using the quantitative polymerase chain reaction (qPCR) by laboratory personnel blinded to participants' characteristics (Crown & Crisp, 1966). The qPCR was run on the Applied Biosystems QuantStudio 6 Flex Real-Time PCR. Relative telomere length is reported as the exponentiated ratio of telomere repeats copy number to a single gene copy number (T: S), as described by (Cawthon, 2002), and corrected in relation to a reference sample. Quality Control (QC) analyses were conducted on two different sets of pooled DNAs extracted from the same blood samples. Each QC sample was plated into several locations within each plate and across multiple plates as study samples were assayed. The combined intra-assay and inter-assay coefficients of variation (CVs) for the telomere was 8.96% for BWHS, 7.00% for MASALA, 10.32 % for NHSII, and 4.68% for SHS. These CVs are within the range of those in other high-quality telomere studies (Zhao et al., 2014).

Statistical analysis

The natural logarithm of relative telomere length (RTL) was transformed to z scores to reduce potential batch effects across the four cohorts. We selected covariates to be included in our analysis using the forward selection method $p < 0.20$. Our initial model adjusted for age. Model 2 included age plus employment status (except for SHS where information was not available), income, and educational attainment (except for NHSII where information was not available). We also adjusted for gender in MASALA and SHS. Model 3 included the additional covariates of BMI, AHEI, and physical activity. Model 4 controlled for the presence of hypertension, and antidepressant use. We created a missing data indicator variable for each measured covariate with missing responses. Generalized linear models with robust standard errors were used to examine the association between depression and telomere length, adjusting for potential confounders by cohorts. In the SHS, generalized estimating equations (GEE) with a working independence correlation structure were used to

account for clustering by family relatedness among participants. We also assessed possible effect modification by dimensions of R/S and social support using Wald tests of the cross-product terms. Analyses were conducted separately within each cohort and a summary effect estimate was calculated using a random-effects model (DerSimonian & Laird, 1986). We used random-effects models because they account for any observed heterogeneity whether or not the heterogeneity is statistically significant. To assess between cohort heterogeneity, we calculated the Q statistic, a measure of the statistical significance of heterogeneity, and the I² index, a measure of the extent of heterogeneity (Higgins et al., 2003). P values were two-sided, with $p < 0.05$ considered to be statistically significant. All statistical analyses were carried out using SAS version 9.4.

Results

Table 1 presents descriptive characteristics of study participants according to the presence of severe depressive symptoms. The prevalence of severe depressive symptoms was considerably higher in BWHS (35%) and SHS (31%) relative to MASALA (10%) and NHSII (9%). Across all cohorts, participants with severe depressive symptoms were more likely to be current smokers. Also, participants with severe depressive symptoms were more likely to be obese and less likely to be physically active (except in NHSII). With regards to religiosity and spirituality, participants with severe depressive symptoms were more likely to describe themselves as not or slightly or moderately spiritual compared to those without severe depressive symptoms: BWHS (60.7% vs. 51.0%), MASALA (87.5% vs. 81.9%), NHSII (67.9% vs. 58.4%), and SHS (72.8% vs. 69.2%) respectively. Concerning participants belonging to a religious community or congregation, the results were mixed. In MASALA and SHS cohorts, individuals with severe depressive symptoms were more likely to belong to a religious community or congregation versus those without severe depressive symptoms (MASALA, 41.7% vs. 30.6% and SHS, 41.5% vs. 40.9%). In BWHS and NHSII, however, individuals with severe depressive symptoms were less likely to belong to a religious community or congregation. Participants with severe depressive symptoms were also more likely to use negative coping strategies across all cohorts: [BWHS 1.6 (0.6) vs. 1.4 (0.4), MASALA 1.8 (0.7) vs. 1.4 (0.6), NHSII 1.4 (0.6) vs. 1.2 (0.4), and SHS 2.0 (0.8) vs. 1.7 (0.7)].

Table 2 presents the multivariable-adjusted percent difference in the log-RTL z-scores. Overall, there were no significant differences in the log-RTL z-scores between participants with severe depressive symptoms versus those without in any single cohort or our pooled analyses: Model 1 [3.2% (-3.9, 10.5) $p=0.37$; p -heterogeneity=0.53], Model 2 [2.0% (-4.9, 9.4); $p=0.63$; p -heterogeneity=0.46], Model 3 [1.0 (-5.8, 8.3); $p=0.76$; p -heterogeneity=0.67], and Model 4 [3.0% (-3.9, 10.5); $p=0.41$; p -heterogeneity=0.67]. Additionally, our secondary analyses using alternative definitions of depression, either including antidepressant use or cross-classifying antidepressant use and depressive symptoms, resulted in similar null results (Supplemental Tables 1 and 2). However, we observed some heterogeneity between studies with the use of antidepressant medication that was not observed in our main analyses (Supplemental Table 2).

Table 3 shows results on severe depressive symptoms stratified by social support, the extent of religiosity, positive religious coping, and negative religious coping and their interactions in the SSSH cohorts and pooled analysis. We observed no statistically significant interactions with social support (p-INT=0.32), extent of religiosity (p-INT=0.54), religious congregation membership (p-INT=0.54), religious service attendance (p-INT=0.44), group prayer (p-INT=0.97), private prayer (p-INT=0.22), positive religious coping (p-INT=0.37), and negative religious coping (p-INT=0.12) in our pooled analysis and there was heterogeneity between studies. However, in specific cohorts, when we stratified by R/S, we observed some significant associations. In MASALA, among participants who described themselves as very religious or spiritual, the difference in log-RTL z-scores between participants with severe depressive symptoms and those without severe depressive symptoms was 214.1 (49.1, 562.0), p-INT=0.18. Among participants in SHS that belong to a religious congregation or membership, severe depressive symptoms were associated with shorter telomere length: -25.6, (-39.5, -8.5) p-INT=0.29. Similarly, among participants in SHS that were involved in frequent group (public) prayer, severe depressive symptoms were associated with shorter telomere length: -56.8 (-76.0, -22.3) p-INT=0.32. However, among NHSII participants that were involved in frequent group (public) prayer, the difference in log-RTL z-scores between participants with severe depressive symptoms and those without severe depressive symptoms was 88.2 (9.6, 223.0) p-INT=0.29.

Discussion

Our racially and ethnically diverse study population did not observe an association between severe depressive symptoms and relative leukocyte telomere length in pooled analyses. However, we observed some significant differences in telomere length limited to specific cohorts when stratified by the extent of religiosity, group prayer, and religious congregation membership. In SHS, the presence of severe depressive symptoms was associated with shorter telomere length among those belonging to a religious community or engaging in group prayer. In MASALA and NHSII, severe depressive symptoms were associated with longer telomere length among the very religious/spiritual and those engaging in frequent prayer, respectively. Other aspects of R/S, as well as social support, did not appear to be important effect modifiers of the depression-RTL relationship.

Multiple studies have examined the cross-sectional relationship between depression and telomere length and found inverse associations, including a previous SHS study (Lin et al., 2016; Ridout et al., 2016; Schutte & Malouff, 2015; Zhao et al., 2016). Our study did not observe this, despite using a common laboratory to conduct the assays and carefully harmonizing data on depressive symptoms. This lack of association in part may be due to the different time periods in our study between assessment of severe depressive symptoms and collection of blood samples for RTL measurement, although we did not observe study-specific associations for MASALA, which had more concurrent measures. This is consistent with the more mixed associations observed in studies that examined prospective changes in RTL after depression assessment with 2 to 11 years of follow-up (Chang, Crous-Bou, et al., 2018a, 2018b; Hoen et al., 2011; Hoen et al., 2013; Rius-Ottenheim et al., 2012; Shalev et al., 2014; Vance et al., 2018; Verhoeven et al., 2019; Verhoeven et al., 2018; Verhoeven et al., 2016). Most studies did not observe a relationship. One reason for differences across

studies is that depressive symptoms can wax and wane over time – it is possible that associations may be restricted to those with chronic depression, which could vary across study populations. Further, the trigger for the depression (e.g., early life abuse, serious health condition, etc.) may be associated with RTL as opposed to depression per se, which could vary across populations. Also, it may be that shorter telomere length is associated with the onset of depression (Chang, Prescott, et al., 2018), but not the other way around, which is supported by consistency in cross-sectional—but not in prospective—studies. Additional research evaluating these is warranted.

The conflicting findings could also be explained by differences in study populations and the method of depression assessment. Our study included healthy, middle-aged population-based study participants, while other prospective studies finding significant results have included relatively young participants (Shalev et al., 2014; Verhoeven et al., 2018). Also, we ascertained depression using the MHI-5 and CES-D scales, two widely used screening instruments for clinical depression (Radloff, 1977; Ware, 2000). To our knowledge, three prospective studies have used the MHI-5 or CES-D instruments to ascertain the presence of depression with null (Chang, Crous-Bou, et al., 2018a, 2018b) and marginally significant findings (Verhoeven et al., 2018). Of the four known prospective studies to have found an association between depression and telomere length, three observed significantly shorter telomere length after following participants with a diagnosis of major depression/major depressive disorder assessed by the *Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-III-R)* or *Fourth Edition (DSM-IV)* (Shalev et al., 2014; Vance et al., 2018; Verhoeven et al., 2016). Thus, it is possible that the relationship between depression and telomere length may be sensitive to the method used to define depression or depression severity. We were unable to delineate between chronic, remitted, or recurrent major depressive disorder, which may explain our non-significant findings in the main results.

We found no evidence of effect modification of the depression-telomere length association by R/S and social support in our pooled analysis. However, in cohort-specific analyses, there was some evidence of effect modification by the extent of religiosity or spirituality, religious congregation membership, and group prayer. The observed significant differences when we stratified by R/S in cohort-specific analyses may have been due to chance since findings were not consistent across studies, and we did not observe an overall association between severe depressive symptoms and RTL in our study populations. This study is the first we are aware of to have considered several measures of religiosity and spirituality in the association between depression and telomere length. Future studies are needed to evaluate these interactions, particularly in populations for whom depression is associated with RTL. From a biological perspective, it has been hypothesized that R/S practices enhance optimal immune functioning and reduce cellular damage during stressful or adverse conditions (Hill et al., 2016; Koenig et al., 2012).

The strengths of this study include our diverse racial/ethnic study participants, adjustments for several confounders, and a relatively long follow-up period of community-dwelling participants in our prospective analyses. This study is also the first known study to investigate the dynamics between depression and telomere length by multiple dimensions

of religiosity and spirituality. However, several limitations should also be noted. Although RTL assays were performed in the same laboratory for all participating cohorts, samples were run at different times, increasing the likelihood of batch effects. To deal with this, we computed z-scores of log-RTL in our cohort-specific and meta-analyses. While we utilized a prospective design in three cohorts, our findings from MASALA participants are based on cross-sectional data. Additionally, RTL was based on the one-time measurement and not repeated measures. Further, there are differences in cohort data collection, measurement, and time points of exposures and measurements. We also observed statistical heterogeneity across the cohorts, which we attempted to minimize through thoughtful harmonization. Finally, although selected participants were from racial/ethnic diverse populations across the U.S., our findings may not be generalizable to all segments of those populations. For example, SHS participants were mainly from the Dakotas and do not represent all American Indians; South Asians in the MASALA study are recruited predominantly from the San Francisco and Chicago areas and represent a disproportionately higher SES group of South Asians.

In conclusion, we observed no association between depression and telomere length across four distinct racial/ethnic populations in the U.S. Further research is needed to investigate the relationship between depression and especially in diverse/ racial-ethnic populations, and the resources of resiliency including dimensions of religiosity and spirituality that may impact the dynamics between depression, telomere length, and risk of future disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding

This is a paper of the National Consortium on Psychosocial Stress, Spirituality, and Health. This work was supported by The John Templeton Foundation (Grant #59607, A.E. Shields). The Black Women's Health Study is supported by National Institutes of Health (NIH) grants R01CA058420, U01CA164974, and R01CA098663. The MASALA Study was supported by NIH grants 1R01HL093009, 2R01HL093009, R01HL120725, UL1RR024131, UL1TR001872, and P30DK098722. The Nurses' Health Study II was supported by NIH grants U01CA176726, R01CA163451, and R01CA67262. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The Strong Heart Study was supported by cooperative agreement grants U01HL41642, U01HL41652, U01HL41654, U01HL65520, and U01HL65521 and research grants R01HL109315, R01HL109301, R01HL109284, R01HL109282 and R01HL109319 from the NIH National Heart, Lung, and Blood Institute.

References

- Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, & Svenningsson P (2011). Depression in Parkinson disease--epidemiology, mechanisms and management. *Nat Rev Neurol*, 8(1), 35–47. 10.1038/nrneurol.2011.189 [PubMed: 22198405]
- Bailey RK, Mokonogho J, & Kumar A (2019). Racial and ethnic differences in depression: current perspectives. *Neuropsychiatr Dis Treat*, 15, 603–609. 10.2147/ndt.s128584 [PubMed: 30863081]
- Berkman L, Carney R, Blumenthal J, Czakowski S, Hosking J, Jaffe A, Babyak M, Carels R, Coleman E, & Curtis S (2000). Enhancing recovery in coronary heart disease patients (ENRICH): study design and methods. The ENRICH investigators. *Am Heart J*, 139(1 Pt 1), 1–9. 10.1016/s0002-8703(00)90301-6 [PubMed: 10618555]

- Berkman LF, & Syme SL (1979). Social networks, host resistance, and mortality: a nine-year follow-up study of Alameda County residents. *Am J Epidemiol*, 109(2), 186–204. 10.1093/oxfordjournals.aje.a112674 [PubMed: 425958]
- Blackburn EH (2001). Switching and signaling at the telomere. *Cell*, 106(6), 661–673. 10.1016/s0092-8674(01)00492-5 [PubMed: 11572773]
- Bruin MC, Comijs HC, Kok RM, Van der Mast RC, & Van den Berg JF (2018). Lifestyle factors and the course of depression in older adults: A NESDO study. *Int J Geriatr Psychiatry*, 33(7), 1000–1008. 10.1002/gps.4889 [PubMed: 29691948]
- Cawthon RM (2002). Telomere measurement by quantitative PCR. *Nucleic Acids Res*, 30(10), e47. 10.1093/nar/30.10.e47 [PubMed: 12000852]
- Chang SC, Crous-Bou M, Prescott J, Rosner B, Simon NM, Wang W, De Vivo I, & Okereke OI (2018a). Prospective association of depression and phobic anxiety with changes in telomere lengths over 11 years. *Depress Anxiety*, 35(5), 431–439. 10.1002/da.22732 [PubMed: 29486096]
- Chang SC, Crous-Bou M, Prescott J, Rosner B, Simon NM, Wang W, De Vivo I, & Okereke OI (2018b). Relation of long-term patterns in caregiving activity and depressive symptoms to telomere length in older women. *Psychoneuroendocrinology*, 89, 161–167. 10.1016/j.psyneuen.2018.01.005 [PubMed: 29414028]
- Chang SC, Prescott J, De Vivo I, Kraft P, & Okereke OI (2018). Polygenic risk score of shorter telomere length and risk of depression and anxiety in women. *J Psychiatr Res*, 103, 182–188. 10.1016/j.jpsychires.2018.05.021 [PubMed: 29883926]
- Crown S, & Crisp AH (1966). A short clinical diagnostic self-rating scale for psychoneurotic patients. The Middlesex Hospital Questionnaire (M.H.Q.). *Br J Psychiatry*, 112(490), 917–923. 10.1192/bjp.112.490.917 [PubMed: 5970912]
- Danese A, Moffitt TE, Harrington H, Milne BJ, Polanczyk G, Pariante CM, Poulton R, & Caspi A (2009). Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. *Arch Pediatr Adolesc Med*, 163(12), 1135–1143. 10.1001/archpediatrics.2009.214 [PubMed: 19996051]
- DerSimonian R, & Laird N (1986). Meta-analysis in clinical trials. *Control Clin Trials*, 7(3), 177–188. 10.1016/0197-2456(86)90046-2 [PubMed: 3802833]
- Dervic K, Grunebaum MF, Burke AK, Mann JJ, & Oquendo MA (2006). Protective factors against suicidal behavior in depressed adults reporting childhood abuse. *J Nerv Ment Dis*, 194(12), 971–974. 10.1097/01.nmd.0000243764.56192.9c [PubMed: 17164639]
- Egan KJ, von Schantz M, Negrao AB, Santos HC, Horimoto AR, Duarte NE, Goncalves GC, Soler JM, de Andrade M, Lorenzi-Filho G, Vallada H, Taporoski TP, Pedrazzoli M, Azambuja AP, de Oliveira CM, Alvim RO, Krieger JE, & Pereira AC (2016). Cohort profile: the Baependi Heart Study—a family-based, highly admixed cohort study in a rural Brazilian town. *BMJ Open*, 6(10), e011598. 10.1136/bmjopen-2016-011598
- Fetzer Institute. (1999). Multidimensional measurement of religiousness/spirituality for use in health research: A report of the Fetzer Institute/National Institute on aging working group.
- Ford DE, Mead LA, Chang PP, Cooper-Patrick L, Wang NY, & Klag MJ (1998). Depression is a risk factor for coronary artery disease in men: the precursors study. *Arch Intern Med*, 158(13), 1422–1426. 10.1001/archinte.158.13.1422 [PubMed: 9665350]
- Franco-de-Moraes AC, de Almeida-Pititto B, da Rocha Fernandes G, Gomes EP, da Costa Pereira A, & Ferreira SRG (2017). Worse inflammatory profile in omnivores than in vegetarians associates with the gut microbiota composition. *Diabetol Metab Syndr*, 9, 62. 10.1186/s13098-017-0261-x [PubMed: 28814977]
- GBD. (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*, 388(10053), 1545–1602. 10.1016/s0140-6736(16)31678-6 [PubMed: 27733282]
- Gonzalez HM, Tarraf W, Whitfield KE, & Vega WA (2010). The epidemiology of major depression and ethnicity in the United States. *J Psychiatr Res*, 44(15), 1043–1051. 10.1016/j.jpsychires.2010.03.017 [PubMed: 20537350]

- Higgins JP, Thompson SG, Deeks JJ, & Altman DG (2003). Measuring inconsistency in meta-analyses. *Bmj*, 327(7414), 557–560. 10.1136/bmj.327.7414.557 [PubMed: 12958120]
- Hill TD, Ellison CG, Burdette AM, Taylor J, & Friedman KL (2016). Dimensions of religious involvement and leukocyte telomere length. *Soc Sci Med*, 163, 168–175. 10.1016/j.socscimed.2016.04.032 [PubMed: 27174242]
- Hoen PW, de Jonge P, Na BY, Farzaneh-Far R, Epel E, Lin J, Blackburn E, & Whooley MA (2011). Depression and leukocyte telomere length in patients with coronary heart disease: data from the Heart and Soul Study. *Psychosom Med*, 73(7), 541–547. 10.1097/PSY.0b013e31821b1f6e [PubMed: 21597035]
- Hoen PW, Rosmalen JG, Schoevers RA, Huzen J, van der Harst P, & de Jonge P (2013). Association between anxiety but not depressive disorders and leukocyte telomere length after 2 years of follow-up in a population-based sample. *Psychol Med*, 43(4), 689–697. 10.1017/s0033291712001766 [PubMed: 22877856]
- Huang T, Tobias DK, Hruby A, Rifai N, Tworoger SS, & Hu FB (2016). An Increase in Dietary Quality Is Associated with Favorable Plasma Biomarkers of the Brain-Adipose Axis in Apparently Healthy US Women. *J Nutr*, 146(5), 1101–1108. 10.3945/jn.115.229666 [PubMed: 27075907]
- Huang T, Trudel-Fitzgerald C, Poole EM, Sawyer S, Kubzansky LD, Hankinson SE, Okereke OI, & Tworoger SS (2019). The Mind-Body Study: study design and reproducibility and interrelationships of psychosocial factors in the Nurses' Health Study II. *Cancer Causes Control*, 30(7), 779–790. 10.1007/s10552-019-01176-0 [PubMed: 31049751]
- Julin B, Shui I, Heaphy CM, Joshi CE, Meeker AK, Giovannucci E, De Vivo I, & Platz EA (2015). Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer. *Br J Cancer*, 112(4), 769–776. 10.1038/bjc.2014.640 [PubMed: 25562437]
- Kanaya A, Ewing S, Vittinghoff E, Herrington D, Tegeler C, Mills C, & Kandula N (2014). Acculturation and Subclinical Atherosclerosis among U.S. South Asians: Findings from the MASALA study. *J Clin Exp Res Cardiol*, 1(1).
- Kanaya AM, Kandula N, Herrington D, Budoff MJ, Hulley S, Vittinghoff E, & Liu K (2013). Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study: Objectives, Methods, and Cohort Description. In *Clin Cardiol* (Vol. 36, pp. 713–720). 10.1002/clc.22219 [PubMed: 24194499]
- Koenig HG, & Büsing A (2010). The Duke University Religion Index (DUREL): a five-item measure for use in epidemiological studies. *Religions*, 1(1), 78–85.
- Koenig HG, King D, & Carson VB (2012). *Handbook of Religion and Health*.
- Lagisetty PA, Wen M, Choi H, Heisler M, Kanaya AM, & Kandula NR (2016). Neighborhood Social Cohesion and Prevalence of Hypertension and Diabetes in a South Asian Population. *J Immigr Minor Health*, 18(6), 1309–1316. 10.1007/s10903-015-0308-8 [PubMed: 26527589]
- Lavange LM, Kalsbeek WD, Sorlie PD, Aviles-Santa LM, Kaplan RC, Barnhart J, Liu K, Giachello A, Lee DJ, Ryan J, Criqui MH, & Elder JP (2010). Sample design and cohort selection in the Hispanic Community Health Study/Study of Latinos. *Ann Epidemiol*, 20(8), 642–649. 10.1016/j.annepidem.2010.05.006 [PubMed: 20609344]
- Lin PY, Huang YC, & Hung CF (2016). Shortened telomere length in patients with depression: A meta-analytic study. *J Psychiatr Res*, 76, 84–93. 10.1016/j.jpsychires.2016.01.015 [PubMed: 26919486]
- Lu D, Palmer JR, Rosenberg L, Shields AE, Orr EH, DeVivo I, & Cozier YC (2019). Perceived racism in relation to telomere length among African American women in the Black Women's Health Study. *Ann Epidemiol*, 36, 33–39. 10.1016/j.annepidem.2019.06.003 [PubMed: 31387775]
- Mather KA, Jorm AF, Parslow RA, & Christensen H (2011). Is telomere length a biomarker of aging? A review. *J Gerontol A Biol Sci Med Sci*, 66(2), 202–213. 10.1093/gerona/glq180 [PubMed: 21030466]
- McHorney CA, Ware JE Jr., Lu JF, & Sherbourne CD (1994). The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. *Med Care*, 32(1), 40–66. 10.1097/00005650-199401000-00004 [PubMed: 8277801]
- Mitchell PH, Powell L, Blumenthal J, Norten J, Ironson G, Pitula CR, Froelicher ES, Czajkowski S, Youngblood M, Huber M, & Berkman LF (2003). A short social support measure for patients

- recovering from myocardial infarction: the ENRICHD Social Support Inventory. *J Cardiopulm Rehabil*, 23(6), 398–403. 10.1097/00008483-200311000-00001 [PubMed: 14646785]
- North KE, Howard BV, Welty TK, Best LG, Lee ET, Yeh JL, Fabsitz RR, Roman MJ, & MacCluer JW (2003). Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. *Am J Epidemiol*, 157(4), 303–314. 10.1093/aje/kwf208 [PubMed: 12578801]
- Pan A, Okereke OI, Sun Q, Logroscino G, Manson JE, Willett WC, Ascherio A, Hu FB, & Rexrode KM (2011). Depression and incident stroke in women. *Stroke*, 42(10), 2770–2775. 10.1161/strokeaha.111.617043 [PubMed: 21836097]
- Pan A, Sun Q, Okereke OI, Rexrode KM, & Hu FB (2011). Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. *Jama*, 306(11), 1241–1249. 10.1001/jama.2011.1282 [PubMed: 21934057]
- Pargament KI, Koenig HG, & Perez LM (2000). The many methods of religious coping: development and initial validation of the RCOPE. *J Clin Psychol*, 56(4), 519–543. 10.1002/(sici)1097-4679(200004)56:4<519::aid-jclp6>3.0.co;2-1 [PubMed: 10775045]
- Park LT, & Zarate CA (2019). Depression in the Primary Care Setting. *N Engl J Med*, 380(6), 559–568. 10.1056/NEJMcp1712493 [PubMed: 30726688]
- Radloff LS (1977). The CES-D Scale: A self-report depression scale for research in the general population [Article]. *Applied Psychological Measurement*, 1, 385–401.
- Reichert S, & Stier A (2017). Does oxidative stress shorten telomeres in vivo? A review. *Biol Lett*, 13(12). 10.1098/rsbl.2017.0463
- Ridout KK, Ridout SJ, Price LH, Sen S, & Tyrka AR (2016). Depression and telomere length: A meta-analysis. *J Affect Disord*, 191, 237–247. 10.1016/j.jad.2015.11.052 [PubMed: 26688493]
- Rius-Ottenheim N, Houben JM, Kromhout D, Kafatos A, van der Mast RC, Zitman FG, Geleijnse JM, Hageman GJ, & Giltay EJ (2012). Telomere length and mental well-being in elderly men from the Netherlands and Greece. *Behav Genet*, 42(2), 278–286. 10.1007/s10519-011-9498-6 [PubMed: 21870178]
- Rosenberg L, Adams-Campbell L, & Palmer JR (1995). The Black Women's Health Study: a follow-up study for causes and preventions of illness. *J Am Med Womens Assoc* (1972), 50(2), 56–58. [PubMed: 7722208]
- Rotella F, & Mannucci E (2013). Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. *Diabetes Res Clin Pract*, 99(2), 98–104. 10.1016/j.diabres.2012.11.022 [PubMed: 23265924]
- Sanders JL, & Newman AB (2013). Telomere length in epidemiology: a biomarker of aging, age-related disease, both, or neither? *Epidemiol Rev*, 35, 112–131. 10.1093/epirev/mxs008 [PubMed: 23302541]
- Schutte NS, & Malouff JM (2015). The association between depression and leukocyte telomere length: a meta-analysis. *Depress Anxiety*, 32(4), 229–238. 10.1002/da.22351 [PubMed: 25709105]
- Setty AR, Curhan G, & Choi HK (2007). Smoking and the risk of psoriasis in women: Nurses' Health Study II. *Am J Med*, 120(11), 953–959. 10.1016/j.amjmed.2007.06.020 [PubMed: 17976422]
- Shalev I, Moffitt TE, Braithwaite AW, Danese A, Fleming NI, Goldman-Mellor S, Harrington HL, Houts RM, Israel S, Poulton R, Robertson SP, Sugden K, Williams B, & Caspi A (2014). Internalizing disorders and leukocyte telomere erosion: a prospective study of depression, generalized anxiety disorder and post-traumatic stress disorder. *Mol Psychiatry*, 19(11), 1163–1170. 10.1038/mp.2013.183 [PubMed: 24419039]
- Storti KL, Arena VC, Barmada MM, Bunker CH, Hanson RL, Laston SL, Yeh JL, Zmuda JM, Howard BV, & Kriska AM (2009). Physical activity levels in American-Indian adults: the Strong Heart Family Study. *Am J Prev Med*, 37(6), 481–487. 10.1016/j.amepre.2009.07.019 [PubMed: 19944912]
- Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, Aviv A, & Spector TD (2005). Obesity, cigarette smoking, and telomere length in women. *Lancet*, 366(9486), 662–664. 10.1016/s0140-6736(05)66630-5 [PubMed: 16112303]

- Van Dam NT, & Earleywine M (2011). Validation of the Center for Epidemiologic Studies Depression Scale--Revised (CESD-R): pragmatic depression assessment in the general population. *Psychiatry Res*, 186(1), 128–132. 10.1016/j.psychres.2010.08.018 [PubMed: 20843557]
- Vance MC, Bui E, Hoepfner SS, Kovachy B, Prescott J, Mischoulon D, Walton ZE, Dong M, Nadal MF, Worthington JJ, Hoge EA, Cassano P, Orr EH, Fava M, de Vivo I, Wong KK, & Simon NM (2018). Prospective association between major depressive disorder and leukocyte telomere length over two years. *Psychoneuroendocrinology*, 90, 157–164. 10.1016/j.psyneuen.2018.02.015 [PubMed: 29499556]
- Verhoeven JE, Penninx B, & Milaneschi Y (2019). Unraveling the association between depression and telomere length using genomics. *Psychoneuroendocrinology*, 102, 121–127. 10.1016/j.psyneuen.2018.11.029 [PubMed: 30544003]
- Verhoeven JE, Revesz D, Picard M, Epel EE, Wolkowitz OM, Matthews KA, Penninx B, & Puterman E (2018). Depression, telomeres and mitochondrial DNA: between- and within-person associations from a 10-year longitudinal study. *Mol Psychiatry*, 23(4), 850–857. 10.1038/mp.2017.48 [PubMed: 28348385]
- Verhoeven JE, van Oppen P, Revesz D, Wolkowitz OM, & Penninx BW (2016). Depressive and Anxiety Disorders Showing Robust, but Non-Dynamic, 6-Year Longitudinal Association With Short Leukocyte Telomere Length. *Am J Psychiatry*, 173(6), 617–624. 10.1176/appi.ajp.2015.15070887 [PubMed: 26940806]
- Ware JE Jr. (2000). SF-36 health survey update. *Spine (Phila Pa 1976)*, 25(24), 3130–3139. 10.1097/00007632-200012150-00008 [PubMed: 11124729]
- Wink P, Dillon M, & Larsen B (2005). Religion as Moderator of the Depression-Health Connection: Findings From a Longitudinal Study [research-article]. 10.1177/0164027504270483, 27(2), 197–220. https://doi.org/10.1177_0164027504270483
- Wise LA, Adams-Campbell LL, Palmer JR, & Rosenberg L (2006). Leisure time physical activity in relation to depressive symptoms in the Black Women's Health Study. *Ann Behav Med*, 32(1), 68–76. 10.1207/s15324796abm3201_8 [PubMed: 16827631]
- Wolkowitz OM, Epel ES, Reus VI, & Mellon SH (2010). Depression gets old fast: do stress and depression accelerate cell aging? *Depress Anxiety*, 27(4), 327–338. 10.1002/da.20686 [PubMed: 20376837]
- Zhao J, Zhu Y, Lin J, Matsuguchi T, Blackburn E, Zhang Y, Cole SA, Best LG, Lee ET, & Howard BV (2014). Short leukocyte telomere length predicts risk of diabetes in american indians: the strong heart family study. *Diabetes*, 63(1), 354–362. 10.2337/db13-0744 [PubMed: 23949319]
- Zhao Q, Zhu Y, Yeh F, Lin J, Lee ET, Cole SA, Calhoun D, & Zhao J (2016). Depressive symptoms are associated with leukocyte telomere length in American Indians: findings from the Strong Heart Family Study. *Aging (Albany NY)*, 8(11), 2961–2970. 10.18632/aging.101104 [PubMed: 27870638]

Table 1: Characteristics of study participants according to the presence of severe depressive symptoms

Variable	BWHs (N=976) Depression		MASALA (N=473) Depression		NHSII (N=984) Depression		SHS (N=475) Depression	
	Yes	No	Yes	No	Yes	No	Yes	No
N (%)	341 (35)	638 (65)	48 (10)	425 (90)	84 (9)	900 (91.5)	147 (31)	328 (69)
Log-RTL (mean (SD))	-0.27 (0.7)	-0.27 (0.7)	-0.99 (0.7)	-0.99(0.8)	0.52 (0.7)	0.37 (0.7)	0.12 (1.0)	0.07 (0.9)
Age at blood draw, (mean (SD))	55.9 (7.6)	56.5 (7.4)	55.9 (9.3)	55.5 (9.2)	57.3 (3.8)	57.5 (4.5)	59.7 (13.2)	59.8 (12.6)
Female, n (%)	341 (100)	638 (100)	21 (43.8)	168 (39.8)	84 (100)	900 (100)	118 (80.3)	195 (59.5)
Married, n (%)	131(38.4)	317 (49.7)	39 (81.3)	398 (93.7)	63 (75.0)	736 (82.1)	39(54.9)	67(40.9)
College grad, n (%)	216 (63.3)	456 (71.5)	37(77.1)	391(92.0)	NA	NA	9(6.2)	41 (12.5)
Employed, n (%)	261(76.8)	508 (79.9)	31 (66.0)	317(74.6)	74(89.2)	808(89.9)	NA	NA
Smoking status, n (%)								
Never	248 (72.7)	464 (72.7)	36 (75.0)	349 (82.1)	49 (58.3)	615 (68.3)	48 (32.9)	100 (30.5)
Former	60 (17.6)	134 (21.0)	8 (16.7)	63 (14.8)	22(26.2)	245(27.2)	31(21.2)	88 (26.8)
Current	33(9.7)	40 (6.3)	4(8.3)	13(3.1)	13(15.5)	40(4.4)	67(45.9)	140 (42.7)
Body Mass Index, kg/m ² , n (%)								
<25	83(24.4)	179 (28.2)	3(3)	168(39.6)	44(55.0)	456(53.5)	15(10.3)	49 (14.9)
25-29.9	99(29.1)	190(30.0)	25(52.1)	197(46.5)	24(30.0)	230(27.0)	40(27.4)	78 (23.8)
30	158(46.5)	265(41.8)	8(16.7)	59(13.9)	12(15.0)	167(19.6)	91(62.3)	201 (61.3)
Physical activity, n (%) ^f								
Quintile 5	27(15.7)	74(20.3)	8(16.7)	86(20.2)	17(20.7)	177(19.9)	18(13.7)	68 (22.7)
AHEL, n (%) ^g								
Quintile 5	47 (14.9)	138 (22.7)	5(10.6)	88(21.0)	10(11.9)	177 (19.7)	16 (13.9)	64 (22.6)
Hypertension, n (%)	141 (41.4)	249 (39.0)	23(47.9)	171(40.2)	14 (16.7)	162 (18.0)	31 (21.1)	59 (18.0)
Antidepressant use, n (%)	89 (26.1)	61 (9.6)	7 (14.6)	8 (1.9)	25 (29.8)	115 (12.8)	21 (14.3)	25 (7.6)
Extent of religiosity, n (%)								
Very	134 (39.3)	311 (49.0)	6 (12.5)	77 (18.1)	27 (32.1)	374 (41.6)	40(27.2)	101 (30.8)
Not/Slightly/ Moderately	207 (60.7)	324 (51.0)	42 (87.5)	348 (81.9)	57 (67.9)	526 (58.4)	107 (72.8)	227 (69.2)
Religious congregation								
Yes	222 (65.1)	433 (68.2)	20 (41.7)	130 (30.6)	38 (45.2)	582 (64.6)	61 (41.5)	134 (40.9)

Variable	BWHHS (N=976) Depression		MASALA (N=473) Depression		NHSII (N=984) Depression		SHS (N=475) Depression	
	Yes	No	Yes	No	Yes	No	Yes	No
No	119 (57.2)	202(31.8)	28 (58.3)	295 (69.4)	46 (54.8)	318 (35.3)	86 (58.5)	194 (59.2)
Service attendance, %								
1/week	146 (42.8)	283 (44.6)	12 (25.0)	90 (21.2)	26 (31.0)	406 (45.1)	36 (24.5)	53 (16.2)
Private prayer (self), %								
1/day	253 (74.2)	496 (78.1)	35 (72.9)	246 (57.9)	41 (48.8)	531 (59.0)	99 (67.4)	227 (69.2)
Group prayer, % 1/day	19 (5.6)	60 (9.5)	1 (2.1)	.8 (4.2)	2 (2.4)	56 (6.2)	17 (11.6)	26 (7.9)
Positive religious coping mean (SD)	3.1 (0.8)	3.2 (0.7)	3.0 (0.7)	2.6 (0.9)	2.6 (1.0)	2.8 (0.9)	2.9 (0.8)	2.8 (0.9)
Negative religious coping mean (SD)	1.6 (0.6)	1.4 (0.4)	1.8 (0.7)	1.4 (0.6)	1.4 (0.6)	1.2 (0.4)	2.0(0.8)	1.7 (0.7)

¹Value is MET hours per week in NHSII, BWHHS, and MASALA, and steps per week in SHS

². AHEL- Alternative Healthy Eating Index

NA-Not available

Table 2:

Depression and log-transformed relative leukocyte telomere length

Cohorts	Depression	N	Model 1		Model 2		Model 3		Model 4	
			% Difference (95% CI)	P-value	% Difference (95% CI)	P-value	% Difference (95% CI)	P-value	% Difference (95% CI)	P-value
BWHS	No	635	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	Yes	341	-0.6 (-9.2, 8.2)	0.89	0.0 (-8.7, 9.6)	0.99	-0.1 (-8.8, 9.5)	0.99	1.9 (-7.0, 11.6)	0.69
MASALA	No	425	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	Yes	48	2.4 (-15.0, 23.6)	0.80	0.8 (-16.8, 22.1)	0.94	-0.7 (-18.0, 20.2)	0.94	3.7 (-14.7, 26.0)	0.71
NHSII	No	900	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	Yes	84	13.5 (-2.5, 32.3)	0.10	12.9 (-3.2, 31.8)	0.12	9.5 (-6.0, 27.5)	0.64	10.7 (-5.2, 29.2)	0.20
SHS	No	328	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	Yes	147	4.8 (-12.4, 25.2)	0.61	-6.6 (-23.5, 14.0)	0.50	-5.2 (-22.3, 15.7)	0.60	-5.3 (-22.8, 16.1)	0.60
Pooled	No	2288	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	Yes	620	3.2 (-3.9, 10.5)	0.37	2.0 (-4.9, 9.4)	0.63	1.0 (-5.8, 8.3)	0.76	3.0 (-3.9, 10.5)	0.41
P-het			0.53		0.46		0.67		0.67	

BWHS

Model 1: Adjusted for age; Model 2: Model 1 plus employment status, income, and educational attainment; Model 3: Model 2 plus BMI, alternative healthy eating index with alcohol, and physical activity; Model 4: Model 3 plus the presence of hypertension and use of antidepressants.

MASALA

Model 1: Adjusted for age; Model 2: gender, employment status, income, and educational attainment; Model 3: Model 2 plus BMI, alternative health eating index, and physical activity; Model 4: Model 3 plus the presence of hypertension and use of antidepressants.

NHSII

Model 1 adjusted for age; Model 2: Model 1 plus employment status, and income; Model 3: Model 2 plus BMI, alternative health eating index, and physical activity; Model 4: Model 3 plus the presence of hypertension and use of antidepressants.

SHS

Model 1: Adjusted for age; Model 2: Model 1 plus gender, income, and educational attainment; Model 3: Model 2 plus BMI, alternative healthy eating index, and physical activity; Model 4: Model 3 plus the presence of hypertension, and use of antidepressants

P-het: p-value for heterogeneity between studies

Table 3.

Depression and log-transformed relative telomere length stratified by social support, religion, and spiritual dimensions

Cohort	Depression	Emotional support				Extent of Religion/Spirituality				Religious congregation membership					
		No		Yes		Not, Slightly or Moderately Religious or Spiritual		Very Religious or < Spiritual		No		Yes			
		N	% Difference (95% CI)	N	% Difference (95% CI)	N	% Difference (95% CI)	N	% Difference (95% CI)	N	% Difference (95% CI)	N	% Difference (95% CI)		
BWHS	No	37	Ref	596	Ref	324	Ref	311	Ref	202	Ref	433	Ref	0.95	
	Yes	48	-9.9 (-34.9, 24.7)	292	1.5 (-7.8, 11.7)	207	-1.1 (-12.4, 11.7)	134	7.5 (-7.0, 24.3)	119	2.8 (-12.8, 21.1)	222	3.1 (-7.4, 14.9)		
MASALA	No	25	Ref	400	Ref	348	Ref	77	Ref	295	Ref	130	Ref	0.75	
	Yes	21	-8.9 (18.8, -35.0)	27	11.2 (-11.2, 39.2)	42	-2.2 (-21.3, 21.5)	6	214.1 (49.1, 562.0)	28	3.7 (-19.6, 33.8)	20	12.9 (-18.8, 56.8)		
NSHSII	No	87	Ref	813	Ref	526	Ref	374	Ref	318	Ref	582	Ref	0.54	
	Yes	19	15.7 (-15.1, 57.6)	65	13.0 (-5.5, 35.1)	57	8.2 (-9.9, 30.0)	27	11.9 (-17.2, 51.1)	46	11.7 (-8.9, 37.0)	38	20.3 (-6.1, 54.0)		
SHS	No	40	Ref	288	Ref	227	Ref	101	Ref	194	Ref	134	Ref	0.29	
	Yes	38	47.3 (-18.0, 164.5)	109	-11.6 (-28.9, 9.9)	107	-4.4 (-23.2, 19.0)	40	5.1 (-22.5, 42.6)	86	7.3 (-16.6, 37.9)	61	-25.6 (-39.5, -8.5)		
Pooled	No	189	Ref	2097	Ref	1425	Ref	863	Ref	1009	Ref	1279	Ref	0.54	
	Yes	126	3.0 (-4.9, 23.4)	593	3.0 (-5.8, 11.6)	413	0.0 (-7.7, 9.4)	207	18.5 (-6.8, 50.7)	279	6.2 (-4.9, 17.4)	341	0.0 (-18.1, 20.9)		
Religious service attendance															
Private Prayer															
Not frequent															
Cohort	Depression	N	% Difference (95% CI)	N	% Difference (95% CI)	N	% Difference (95% CI)	N	% Difference (95% CI)	N	% Difference (95% CI)	N	% Difference (95% CI)	N	% Difference (95% CI)
BWHS	No	352	Ref	283	Ref	139	Ref	496	Ref	575	Ref	60	Ref	0.55	
	Yes	195	0.6 (-11.2, 14.0)	146	4.7 (-8.1, 19.3)	88	6.6 (-9.5, 25.6)	253	-1.1 (-11.1, 10.1)	322	2.1 (-7.2, 12.2)	19	18.6 (-4.2, 46.7)		
MASALA	No	335	Ref	90	Ref	179	Ref	246	Ref	407	Ref	18	Ref	0.07	
	Yes	36	-1.1 (20.7, 23.3)	12	49.8 (-7.3, 142.2)	13	8.5 (-23.8, 54.5)	35	5.7 (-17.6, 35.6)	47	6.5 (-12.6, 29.9)	1	Negligible		
Group Prayer															
Not frequent															
Frequent (1/week)															

Cohort	Depression	Emotional support				Extent of Religion/Spirituality				Religious congregation membership							
		N	% Difference (95% CI)	Above Median N	% Difference (95% CI)	N	% Difference (95% CI)	Above Median N	% Difference (95% CI)	N	% Difference (95% CI)	Above Median N	% Difference (95% CI)				
NSHSII	No	494	Ref	406	Ref	0.95	369	Ref	531	Ref	0.71	844	Ref	56	Ref	0.00	
	Yes	58	13.3 (-5.4, 35.6)	26	15.9 (-15.7, 59.2)		43	13.0 (-7.6, 38.2)	41	8.5 (-15.0, 38.6)		82	9.1 (-6.9, 27.7)	2	88.2 (9.6, 223.0)		
SHS	No	275	Ref	53	Ref	0.20	101	Ref	227	Ref	0.68	302	Ref	26	Ref	0.32	
	Yes	111	-11.3 (-26.3, 6.7)	36	12.5 (-27.8, 75.2)		48	7.5 (-20.6, 45.4)	99	-6.6 (-24.5, 15.5)		130	-3.8 (-23.3, 20.7)	17	-56.8 (-76.0, -22.3)		
Pooled	No	1456	Ref	832	Ref	0.44	788	Ref	1500	Ref	0.22	2128	Ref	160	Ref	0.97	
	Yes	400	5.1 (-3.0, 13.9)	220	9.4 (-3.0, 22.1)	192		8.3 (-3.0, 22.1)	428	0.0 (-8.6, 8.3)		581	3.0 (-3.9, 11.6)	39	1.0 (-48.3, 97.4)		
Negative Religious Coping																	
		Positive Religious Coping				Negative Religious Coping											
		At or below the median				Above Median				At or below the median				Above Median			
Cohort	Depression	N	% Difference (95% CI)	Above Median N	% Difference (95% CI)	P-INT	N	% Difference (95% CI)	Above Median N	% Difference (95% CI)	P-INT	N	% Difference (95% CI)	Above Median N	% Difference (95% CI)	P-INT	
BWHS	No	360	Ref	266	Ref	0.50	339	Ref	287	Ref	0.21						
	Yes	191	2.1 (-10.2, 16.2)	141	-1.2 (-13.5, 12.9)		122	7.3 (-7.0, 23.9)	210	-6.9 (-17.7, 5.4)							
MASALA	No	197	Ref	172	Ref	0.33	206	Ref	163	Ref	0.30						
	Yes	15	19.6 (-11.5, 61.5)	29	11.2 (-14.7, 45.1)		10	32.9 (-8.8, 93.9)	34	-7.8 (-28.3, 1.7)							
NSHSII	No	420	Ref	360	Ref	0.55	451	Ref	329	Ref	0.75						
	Yes	39	25.4 (-1.3, 59.2)	31	8.0 (-16.2, 39.3)		34	26.3 (-4.0, 66.1)	36	10.5 (-10.9, 37.1)							
SHS	No	177	Ref	125	Ref	0.49	184	Ref	118	Ref	0.37						
	Yes	71	4.2 (-18.9, 33.7)	58	-16.1 (-37.2, 12.1)		57	0.2 (-19.1, 24.2)	72	-14.5 (-38.2, 18.2)							
Pooled	No	1154	Ref	923	Ref	0.37	1180	Ref	897	Ref	0.12						
	Yes	316	8.3 (-2.0, 18.5)	259	0.0 (-9.5, 10.5)		223	9.4 (-1.0, 22.1)	352	-4.9 (-13.1, 5.1)							

BWHS: Adjusted for age, employment status, income, educational attainment, BMI, alternative healthy eating index with alcohol physical activity, the presence of hypertension, and use of antidepressants.
MASALA: Adjusted for age; gender, employment status, income, and educational attainment; BMI, alternative health eating index, and physical activity, presence of hypertension, and use of antidepressants.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

NHSII: Adjusted for age, employment status, income, BMI, alternative health eating index, physical activity, the presence of hypertension, and use of antidepressants.

SHS: Adjusted for age, gender, income, and educational attainment, BMI, alternative healthy eating index, physical activity, the presence of hypertension, and use of antidepressants

Pooled estimates were assessed through a random effect meta-analysis

P-int: P-interaction